REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
06/06/2026
Voltar para busca
Dado oficial do USPTO
ANEMOCYTE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ANEMOCYTE
ST13
US500000079188650Classe
5, 10, 42
Pedido
79188650
Registro
5215720
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
61
Atualização mais recente
07/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 42
Data de depósito
11/09/2015
Data de registro
06/06/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/02/2025
Última transação
07/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
GERENZANO (VA), IT
Examinador
SAUNDERS, ANDREA DAWN
Unidade examinadora
P10
Localização atual
TMO LAW OFFICE 137
Titulares e representantes
Titulares
ANEMOCYTE S.R.L.
ARETA INTERNATIONAL S.R.L.
Representantes
Brian A. Tollefson Tollefson IP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparationsrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposesrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachetssyringesinfusion bagsvials and pharmaceutical preparations for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; biological preparations for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; chemical preparations for pharmaceutical purposesrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; preparations for diagnostics for medical purposes; drugsrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; organic products for medical usenatural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genessomatic cellsgenetically modified cellsviral vectorsnucleic acids and engineered tissues; products for somatic cell therapyadult stem cellst-cellsb-cellsnk cellsdendritic cellsmonocytesmacrophagesadipocyteskeratinocyteserythrocytesplateletsproducts for gene therapygenetically modified cellsviral vectorsnucleic acids; tissue engineered productscells and tissues that have been subjected to extensive manipulation and are used with the aim to repairreplace or restore a lost or impaired tissue or function; products for regenerative medicinecells and tissues that have been subjected to extensive manipulation and are used with the aim to repairreplacerestore or promote the repairreplacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acidsnucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissuesbiological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodiesbuffersreagents for use in disease treatment and therapy
Classe 10
Surgical apparatus and instruments for medicaldental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human bodyin particular syringes and catheters; medical equipmentcentrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposesboth in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients
Classe 42
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological servicesscientific research in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
61 publicações encontradas
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
04/06/2026
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
12/05/2026
INPC
INVALIDATION PROCESSED
12/05/2026
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
26/03/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
28/10/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
30/09/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
03/07/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
28/02/2025
71AG
REGISTERED-SEC.71 ACCEPTED
28/02/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
15/11/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
25/10/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
21/08/2024
PR71
POST REGISTRATION ACTION MAILED - SEC.71
24/02/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/02/2024
ES71
TEAS SECTION 71 RECEIVED
05/06/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
24/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/10/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
24/10/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
24/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
24/10/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/06/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/04/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
22/02/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/10/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/09/2017
FIMP
FINAL DISPOSITION PROCESSED
14/09/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/09/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
06/06/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/03/2017
PUBO
PUBLISHED FOR OPPOSITION
21/03/2017
GPNX
NOTIFICATION PROCESSED BY IB
17/03/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/03/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/03/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
14/02/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
01/02/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/02/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
01/02/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/02/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/01/2017
GNFR
FINAL REFUSAL E-MAILED
08/01/2017
CNFR
FINAL REFUSAL WRITTEN
08/01/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/12/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/12/2016
ALIE
ASSIGNED TO LIE
07/12/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/11/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/10/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/10/2016
RFNT
REFUSAL PROCESSED BY IB
29/07/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
13/07/2016
RFRR
REFUSAL PROCESSED BY MPU
13/07/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/07/2016
MAFR
APPLICATION FILING RECEIPT MAILED
12/07/2016
CNRT
NON-FINAL ACTION WRITTEN
11/07/2016
DOCK
ASSIGNED TO EXAMINER
08/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/07/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ANEMOCYTE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.